Cord Blood News 8.27 July 14, 2016 | |
| |
TOP STORYIn this multicenter, double-blind, randomized controlled trial, researchers investigated the incidence and severity of chronic graft-versus-host disease among patients, and the changes in T, B, and natural killer cells after the repeated infusion of mesenchymal stromal cells. [J Clin Oncol] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia At high effector to target ratios, CD123-T cells secreting bispecific engager molecules recognized normal hematopoietic stem and progenitor cells (HSPCs) with preferential recognition of HSPCs from cord blood compared to bone marrow. [Mol Ther] Abstract Scientists found that umbilical cord-derived mesenchymal stem cells reduced scar formation and myofibroblast accumulation in a skin-defect mouse model. [Stem Cells Transl Med] Abstract Scientists studied the remyelinating potential of human Wharton’s jelly mesenchymal stem cells after intranasal delivery. [Stem Cells Dev] Abstract Researchers compared chronic GvHD incidence, immunosuppression burden and late infections and hospitalizations in consecutive patients undergoing cord blood transplantation versus peripheral blood matched unrelated donors transplant at their center between June 2009 and April 2014. [Bone Marrow Transplant] Abstract Factor Predicting Total Nucleated Cell Counts in Cord Blood Units The efficacy of stem cells in umbilical cord blood can be predicted by the number of total nucleated cells (TNCs). To optimize the clinical use of stem cells in our population, scientists addressed several variables affecting the TNC count. [Transfusion] Abstract Researchers retreated cord blood and peripheral blood mononuclear and human mast cells with specific signaling molecule inhibitors such as BAY117082, PD98059 and LY294002 and then stimulated with LPS and PGN and assayed for cytokines IL-6, IL-12/IL-23p40 (Th1), IL-13 (Th2), IL-23 (Th17) and RANTES secretion. [Cytokine] Abstract Investigators demonstrated that human umbilical cord mesenchymal stem cells attenuated both lung lymphocyte and eosinophil infiltration, and significantly decreased the concentration of Th2 cytokines interleukin-5 in splenocyte cultures. [Inflamm Res] Abstract | |
| |
REVIEWSThere are still several challenges in the clinical translation of mesenchymal stem cell (MSC) therapy, such as safety, optimal dose of administration, optimal mode of cell delivery, issues of MSC heterogeneity, clinically meaningful engraftment, autologous or allogeneic approach, challenges with cell manufacture, and further mechanisms. [Cell Death Disc] Full Article Visit our reviews page to see a complete list of reviews in the cord blood research field.
| |
INDUSTRY NEWSKiadis Pharma N.V. announced that its partnership with The Leukemia & Lymphoma Society (LLS) has been strengthened with a second equity investment by LLS into the development of Kiadis Pharma’s lead product ATIR101™. [Kiadis Pharma N.V.] Press Release Juno Therapeutics Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial Juno Therapeutics, Inc. announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. The clinical hold was initiated after two patient deaths, which followed the recent addition of fludarabine to the pre-conditioning regimen. [Juno Therapeutics, Inc.] Press Release | |
From our sponsor: Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.
| |
POLICY NEWSSelling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. [Cell Stem Cell] Editorial The Past, Present and Future of the PhD Thesis According to one of those often-quoted statistics that should be true but probably isn’t, the average number of people who read a PhD thesis all the way through is 1.6. And that includes the author. More interesting might be the average number of PhD theses that the typical scientist — and reader of Nature — has read from start to finish. [Nature News] Editorial Beat It, Impact Factor! Publishing Elite Turns against Controversial Metric A paper posted to the preprint server bioRxiv, authored by senior employees at several leading science publishers (including Nature’s owner, SpringerNature), calls on journals to downplay the figure in favor of a metric that captures the range of citations that a journal’s articles attract. [Nature News] Editorial | Article
| |
EVENTSNEW Moving Forward with Stem Cell Therapy 2016 Visit our events page to see a complete list of events in the cord blood community.
| |
JOB OPPORTUNITIESNEW Assistant Member Faculty – PlatinumImmunotherapy (Fred Hutchinson Cancer Research Center) NEW Cell Biologist – Mesenchymal Stem Cells (Biostage) Technical Sales Representative (STEMCELL Technologies Inc.) PhD Studentship – Various Projects (Vienna Biocenter) Copy Editor – Nature Reviews Molecular Biology (Springer Nature) Postdoctoral Fellow – Characterizing and Targeting Cancer Stem Cells (City of Hope) Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University) Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London) Postdoctoral Research Associate – TAM-Family Kinases in Leukemogenesis (Emory University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cord Blood News Volume 8.27 | Jul 14 2016